Did you mean 903452 02 0?
Displaying drugs 501 - 525 of 1410 in total
HCV-086
HCV-086 is a small molecule antiviral designed to block an enzyme required for the replication of the hepatitis C virus.
Investigational
TSN-084
Investigational
MK-0812
MK0812 has been used in trials studying the treatment of Relapsing-Remitting Multiple Sclerosis.
Investigational
MK-0893
MK0893 has been used in trials studying the treatment of Type 2 Diabetes Mellitus and Diabetes Mellitus, Type 2.
Investigational
MK-0873
MK-0873 has been used in trials studying the treatment of Rheumatoid Arthritis.
Investigational
TMV-083
TMV-083 is an attenuated live virus COVID-19 vaccine candidate which employs the measles vaccine as a vector . It expresses a spike protein antigen from SARS-CoV-2 .
Investigational
alpha-Hydroxylinoleic acid
alpha-Hydroxylinoleic acid is under investigation in clinical trial NCT04431258 (ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study).
Investigational
AMT-080
AMT-080 is an investigational gene therapy being investigated for the treatment of Duchenne muscular dystrophy.
Investigational
PRX-08066
Investigational
UK-396,082
UK-396,082 has been used in trials studying the basic science of Safety, Phase 1, Toleration, Multiple Dose, and Pharmacokinetic.
Investigational
GDC-0810
ARN-810 has been used in trials studying the basic science and treatment of Breast Cancer.
Investigational
RGG0853
RGG0853 is an E1A lipid complex, a repressor gene complexed with a cationic lipid vector.
Investigational
CK0802
CK0802 is an off-the-shelf product composed of allogeneic umbilical cord blood derived regulatory T-cells (T-Reg cells), which can be used intravenously and without HLA matching. On the surface of these T-Reg cells, T-cell lung homing markers are expressed.
Investigational
INCB-086550
INCB-086550 is under investigation in clinical trial NCT04629339 (Study of INCB086550 in Select Solid Tumors).
Investigational
Icerguastat
Investigational
Saruparib
Saruparib is under investigation in clinical trial NCT06380751 (Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or Palb2m Advanced Breast Cancer).
Investigational
Matched Description: … With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in Hr-positive, Her2-negative (IHC 0, …
Cavrotolimod
Investigational
Asvasiran
Asvasiran is an siRNA that targets the respiratory syncytial virus (RSV) N gene and inhibits viral replication. It has the potential to treat or prevent RSV infection.
Investigational
INS018_055
Investigational
Ivarmacitinib
Ivarmacitinib (SHR0302) is a selective inhibitor of Janus kinase 1 (JAK1) under investigation for the treatment of various immuno-inflammatory conditions. While ivarmactinib has yet to receive marketing authorization, as of February 2022 clinical trials are ongoing or completed evaluating its use in atopic dermatitis,[L40604,L40619,L40629] ankylosing spondylitis, rheumatoid arthritis, psoriatic arthritis,...
Experimental
Investigational
AP-001
Investigational
MPT-0L055
Investigational
BPR-0L075
Investigational
BMN-044
Experimental
Withdrawn
Stamulumab
MYO-029 is a human anti-GDF-8 monoclonal antibody, which is being developed to treat muscle-wasting diseases including muscular dystrophy and age-related sarcopenia.
Investigational
Displaying drugs 501 - 525 of 1410 in total